IP Library Granted Patent US 10,808,246
Granted Patent B2
US 10,808,246 · App. 14/901,945 · Granted Oct 20, 2020

Oligonucleotide-ligand conjugates and process for their preparation

Inventors: Muthiah Manoharan (Cambridge, MA); Jayaprakash K. Nair (Cambridge, MA); Pachamuthu Kandasamy (Cambridge, MA); Shigeo Matsuda (Cambridge, MA); Alexander V. Kelin (Cambridge, MA); Muthusamy Jayaraman (Cambridge, MA); Kallanthottathil G. Rajeev (Cambridge, MA)
Assignee: ALNYLAM PHARMACEUTICALS, INC.
C12N15/113A61K47/549C07H21/00C12N15/111C12N2310/14C12N2310/351C12N2320/30C12N2320/32C12N2330/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,808,246
App. No.
14/901,945
Granted
Oct 20, 2020
Kind
B2
Abstract

The present invention relates to ligand conjugates of iRNA agents (such as siRNA) of the formula

Claims (29)

1. A conjugate of the formula:

wherein

R A is a single stranded or double stranded oligonucleotide having (i) a 3′ end attached to the oxygen atom shown and (ii) a length ranging from 6 to about 30; and

R 3 is selected from the following wherein the arrow → or squiggle indicates the site of conjugation:

2. The conjugate of claim 1 , wherein n is 1-4.

3. The conjugate of claim 1 , wherein the conjugate has the formula:

4. The conjugate of claim 1 , wherein the oligonucleotide moiety in R A is double stranded and has a length ranging from 15 to about 30 nucleotide units.

5. The conjugate of claim 4 , wherein the oligonucleotide moiety has a length ranging from 18 to about 23 nucleotide units.

6. A conjugate of the formula:

wherein

R A is a single stranded or double stranded oligonucleotide having (i) a 3′ end attached to the oxygen atom shown and (ii) a length ranging from 6 to about 30 nucleotide units;

R B is selected from Table 2 or Table 2A

TABLE 2

wherein in Table 2,

each occurrence of Q is independently O, S, or CH 2 ;

each occurrence of Z is independently —CONH—, —NHCO—, —OC(O)NH—, or —NHC(O)O—;

each of R, X and represents the point of attachment to the rest of the conjugate;

each occurrence of R′ is independently Ac, COCF 3 or any amine protecting group compatible with oligonucleotide (RNA/DNA) synthesis and deprotection conditions;

each of the variables l, m, n, p, q, and r independently ranges from about 0 to about 10; and

TABLE 2A

wherein in Table 2A,

each occurrence of Q is independently O, S, or CH 2 ;

each occurrence of Z is independently —CONH—, —NHCO—, —OC(O)NH—, or —NHC(O)O—;

represents the point of attachment to the rest of the conjugate;

each occurrence of R is independently OH or NHAc; and

each of the variables l, m, n, p, q, and r independently ranges from about 0 to about 10.

7. The conjugate of claim 6 , wherein the oligonucleotide moiety in R A is double stranded and has a length ranging from 15 to about 30 nucleotide units.

8. The conjugate of claim 7 , wherein the oligonucleotide moiety has a length ranging from 18 to about 23 nucleotide units.

9. The conjugate of claim 6 , wherein the conjugate has the formula

Assignments (2)
SECURITY INTEREST Recorded Oct 1, 2025
From: ALNYLAM PHARMACEUTICALS, INC.; SIRNA THERAPEUTICS, INC.
To: BANK OF AMERICA, N.A.
Reel/Frame 072996/0337 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 27, 2016
From: MANOHARAN, MUTHIAH; NAIR, JAYAPRAKASH K; KANDASAMY, PACHAMUTHU; MATSUDA, SHIGEO; KELIN, ALEXANDER V; JAYARAMAN, MUTHUSAMY; RAJEEV, KALLANTHOTTATHIL G
To: ALNYLAM PHARMACEUTICALS, INC.
Reel/Frame 039869/0674 →